Russia postpones compulsory licensing of imported drugs until December

10 May 2016
moscow-big

The Russian government has decided to postpone the introduction of a controversial scheme for the compulsory licensing of drugs imported into Russia, as proposed by some local drugmakers, reports The Pharma Letter’s local correspondent.

According to Alia Samigullina, an official spokesman of Arkady Dvorkovich, (Russia’s first deputy prime-minister, who oversees the development of pharmaceutical industry in the Russian government), a significant part of imported drugs with unexpired periods of patent protection is already produced within the territory of Russia, so there is a no need for the introduction of compulsory licensing scheme.

The initiative of compulsory licensing of drugs in Russia was for the first time put forward by Vikram Singh Puniya, head of Pharmasyntez, one of Russia’s leading drugmakers. According to him, such scheme is widely used in the BRICS (Brazil, Russia, India, China and South Africa) markets, in particular India and Brazil, and could be useful for Russia, which in recent years has faced with a shortage of some vital drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical